Author:
Herr D.,Bekes I.,Kreienberg R.
Publisher
Springer Science and Business Media LLC
Subject
Obstetrics and Gynaecology
Reference33 articles.
1. Alaoui-Jamali MA, Qiang H (2003) The interface between ErbB and non-ErbB receptors in tumor invasion: clinical implications and opportunities for target discovery. Drug Resist Updat 6(2):95–107
2. Benz CC, Scott GK, Sarup JC et al (1992) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24(2):85–95
3. Blay JY, Lluch A, Gutierrez M et al (2010) Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study. Cancer Res 70:201
4. Boccardo F, Kaufmann B, Baselga J et al (2008) Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastases (BM) from HER2+ breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d‘Utilisation (ATU) [abstract 1094]. J Clin Oncol 26(15 Suppl):64 s
5. Bolat F, Kayaselcuk F, Nursal TZ et al (2006) Microvessel density, VEGF expression, and tumor-associated macrophages in breast tumors: correlations with prognostic parameters. J Exp Clin Cancer Res 25(3):365–372